SLC10A2 and metabolic disease: Many drugs targeting BA metabolism have been shown to be effective against metabolic diseases, including apical sodium-dependent bile acid transporter (ASBT) inhibitors and FXR agonists/antagonists (Matye et al., 2021a; Matye et al., 2021b; Clifford et al., 2021).